Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye^*

References

• Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocular Surface 2003;1:127–49
   Google Scholar
• Weeks ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1–20
   Google Scholar
• McCarthy CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105:1114–9
   PubMed Web of Science ®Google Scholar
• Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology 2003;110:1096–101
   PubMed Web of Science ®Google Scholar
• Gupta SK, Gupta V, Joshi S, Tandon R. Subclinically dry eyes in urban Delhi: an impact of air pollution? Ophtalmologica 2002;216:368–71
   PubMed Web of Science ®Google Scholar
• Nelson JD. Simultaneous evaluation of tear turnover and corneal epithelial permeability by fluorophotometry in normal subjects and patients with keratoconjunctivitis sicca (KCS). Trans Am Ophthalmol Soc 1995;93:709–53
   PubMedGoogle Scholar
• Fahim MM, Haji S, Koonapareddy CV, et al. Fluorophotometry as a diagnostic tool for the evaluation of dry eye disease. BMC Ophthalmol 2006;6:20
   PubMedGoogle Scholar
• Abdul-Fattah AM, Bhargva HN, Korb DR, et al. Quantitative in vitro comparison of fluorescein delivery to the eye via impregnated strip and volumetric techniques. Invest Ophthalmol Vis Sci 1999;40(Suppl):S544
   Google Scholar
• Marquardt R, Stodtmeiser R, Christ T. Modification of tear film break-up time test for increased reliability. In: Holly FJ, editor. The preocular tear film in health, disease, and contact lens wear. Lubbock (TX): Dry Eye Institute; 1986
   Google Scholar
• Ousler GW, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular surface disease. The Ocular Surface 2005;3:143–54
   PubMed Web of Science ®Google Scholar
• Schindelar M, Ousler III GW, et al. Effect of tear film stability on ocular surface damage in a population of dry eye patients. Invest Ophthalmol Vis Sci 2005;46:E–4457
   Google Scholar
• Ousler GW, Wilcox KA, Gupta G, et al. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004;93:460–4
   PubMed Web of Science ®Google Scholar
• Welch D, Ousler GW, Nally LA, et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population – an evaluation of exaggerated dose effect. Adv Exp Med Biol 2002;506:1051–5
   PubMed Web of Science ®Google Scholar
• Torkildsen G, Abelson MB. Comparison of topical and systemic anti-allergy treatments relative to ocular dryness. Presented at ARVO, 2006
   Google Scholar
• Crandall DC, Leopold IH. The influence of systemic drugs on tear film constituents. Ophthalmology 1979;86:115–25
   PubMed Web of Science ®Google Scholar
• Rios JD, Dartt DA, et al. Immunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion. Invest Ophthalmol Vis Sci 1999;40:1102–11
   PubMed Web of Science ®Google Scholar
• Ousler III GW, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29:611–6
   Google Scholar
• Krokhmal L, Gomes P, Welch D, Abelson MB. The incidence of dry eye with topical anti-allergic therapies. Invest Ophthalmol Vis Sci 2007;48 E–2300
   Google Scholar
• Edwards MR, Pasquine T, Gross RD, Robertson SM. Low frequency of treatment-related ocular adverse events associated with olopatadine 0.2% (Pataday™) in clinical trials. Presented at WSAAI 2007
   Google Scholar
• Welch D, Davis J, Torkildsen G, et al. The effect of olopatadine 0.1% on tear film stability. Presented at: Association for Research in Vision and Ophthalmology annual meeting; April 30–May 4, 2006; Ft. Lauderdale, FL
   Google Scholar
• Dogru M, Ösmen A, Ertürk H, et al. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clin Ther 2002;24:1309–21
   PubMed Web of Science ®Google Scholar
• Rosenwasser LJ, O’Brien T, Weyne J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med Res Opin 2005;21:1377–87
   PubMed Web of Science ®Google Scholar
• Abelson MB, Greiner JV, Gomes P, et al. Olopatadine reduces the ocular itching and redness of allergic conjunctivitis 24 hours after instillation. Presented at Western Society of Allergy, Asthma & Immunology annual meeting; January 19–23, 2003; Wailea, Hawaii
   Google Scholar
• Vogelson C, Abelson M, Pasquine T, et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 2004;25:69–75
   Google Scholar
• Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens 2006;32:272–6
   PubMedGoogle Scholar
• Code of Federal Regulations./person-group>. Title 21, Vol. 5, Sec. 349. 12,349.3,349.6
   Google Scholar
• Göbbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992;99:873–8
   Google Scholar
• Malet F, Karsenti D, Pouliquen P. Preservative-free ocular hydrating agents in symptomatic contact lens wearers: saline versus PVP solution. Eye Contact Lens 2003;29: 38–43
   Google Scholar
• Guillon M, Maissa C, Pouliquen P, Deval L. Effect of povidone 2% preservative-free eyedrops on contact lens wearers with computer visual syndrome: pilot study. Eye Contact Lens 2004;30:34–9
   PubMedGoogle Scholar